bivalirudin (angiomax) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Bivalirudin is a synthetic 20 amino acid peptide rationally designed based on structural studies of hirudin, a naturally occurring anticoagulant. Bivalirudin is sold under the brand name Angiomax and is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). It is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. Bivalirudin directly inhibits thrombin by binding simultaneously to its active catalytic site and its substrate recognition site.   NCATS

Chemistry

  • SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]3CCCN3C(=O)[C@H](N)Cc4ccccc4)C(=O)N5CCC[C@H]5C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc6ccc(O)cc6)C(=O)N[C@@H](CC(C)C)C(=O)O
  • InChIKey: OIRCOABEOLEUMC-GEJPAHFPSA-N
  • Mol. Mass: 2180.32
  • ALogP: Missing data
  • ChEMBL Molecule:
    bivalirudin  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$88.8008 - $523.9580

Australia

$395.8062
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

angiomax | angiox | bg8967 | bg 8967 | bg-8967 | bivalirudin | bivalirudina | bivalirudinum | bivalrudin | ctb-001 | hirulog | hirulog-1 | l-leucine, d-phenylalanyl-l-prolyl-l-arginyl-l-prolylglycylglycylglycylglycyl-l-asparaginylglycyl-l-alpha-aspartyl-l-phenylalanyl-l-alpha-glutamyl-l-alpha-glutamyl-l-isoleucyl-l-prolyl-l-alpha-glutamyl-l-alpha-glutamyl-l-tyrosyl- | phe-pro-arg-pro-(gly)4-asn-gly-asp-phe-glu-glu-ile-pro-glu-glu-tyr-leu | phe-pro-arg-pro-(gly)4 desulfato-tyr63'-hirugen | phe-pro-arg-pro-(gly)4-desulfohirudin-(53-64)

Organizations (103)

Research & Development (80)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (24)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (32)

Approved Indications (3)


 

Angina, Unstable

Thrombocytopenia

Thrombosis

Experimental Indications - Clinical Trial Phases 1-4 (32)


 

Acute Coronary Syndrome (Phase 4)

Acute Disease (Phase 3)

Aged (Phase 4)

Aging (Phase 4)

Angina Pectoris (Phase 4)

Angina, Unstable (Phase 3)

Anticoagulants (Phase 4)

Aortic Stenosis, Subvalvular (Phase 3)

Aortic Valve Disease (Phase 3)

Cardiology (Phase 2)

Cardiovascular Diseases (Phase 3)

Coronary Artery Bypass (Phase 3)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

COVID-19 (Phase 4)

Extracorporeal Membrane Oxygenation (Phase 4)

Healthy Volunteers (Phase 1)

Heart Diseases (Phase 3)

Hematologic Diseases (Phase 3)

Hemorrhage (Phase 3)

Leukemia, Lymphoid (Phase 4)

Myocardial Infarction (Phase 4)

Percutaneous Coronary Intervention (Phase 4)

Pharmacological and Toxicological Phenomena (Phase 4)

ST Elevation Myocardial Infarction (Phase 4)

Subarachnoid Hemorrhage (Phase 3)

Thoracic Surgery (Phase 3)

Thrombocytopenia (Phase 4)

Thrombosis (Phase 4)

Transcatheter Aortic Valve Replacement (Phase 3)

Vascular Diseases (Phase 3)

Venous Thrombosis (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 61
  • # of Trial Organizations: 80

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue